This study investigates advanced solid tumours expressing Claudin18.2. It focuses on understanding the response to treatment.
The study evaluates the safety, tolerability, and other effects of the investigational medication both alone and with other anti-cancer agents.
- Who can participate: Adults aged 18 and older with advanced solid tumours expressing CLDN18.2, who have at least one measurable lesion and meet health criteria, may participate.
- Study details: Participants will receive either the investigational medication alone or in combination with other treatments.